Search company, investor...

Biopure Corporation

Founded Year



Dead | Dead

Total Raised


About Biopure Corporation

Biopure's product is a "blood substitute," or more properly defined as a hemoglobin- based oxygen carrier (HBOCs). The hemoglobin is derived from a bovine source. The product is universally compatible, requiring no blood-typing or cross-matching, and virtually eliminates the risk of transmission of diseases such as AIDS or hepatitis. Biopure has two major products: Hemopure for human use and Oxyglobin for veterinary use.

Headquarters Location

11 Hurley Street

Cambridge, Massachusetts, 02141,

United States


Missing: Biopure Corporation's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Biopure Corporation's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Biopure Corporation Patents

Biopure Corporation has filed 4 patents.

patents chart

Application Date

Grant Date


Related Topics




Pharmaceutical industry, Samurai, Medical equipment, Catheters, Endoscopy


Application Date


Grant Date



Related Topics

Pharmaceutical industry, Samurai, Medical equipment, Catheters, Endoscopy



Latest Biopure Corporation News

Synthetic Blood Substitutes Market Set for Explosive Growth rate (CAGR) of 18.5% by 2027

Sep 6, 2022

According to a recent estimate by Emergen Research, the market for synthetic blood substitutes worldwide is expected to reach USD 15.40 billion by 2027. Due to their expanding use in conditions such as cardiovascular disease, anemia, malignant neoplasm, injuries, neonatal conditions, maternal conditions, organ transplants, and other conditions, synthetic blood substitutes like Hemopure, Oxyglobin, and Hemotech are experiencing double-digit market growth. Additionally, the need for artificial blood replacements is likely to be fueled by obstetric issues associated with blood transfusions that, if improperly managed, can lead to health complications and even death. For critically unwell patients, artificial blood or blood is utilized as a red blood cell substitute. The only function of artificial blood is to deliver oxygen and carbon dioxide to the body. The component is not fully capable of performing the functions of a red blood cell. In the upcoming year, the market is anticipated to be driven by the rising need for blood transfusions. In addition, efforts to produce effective artificial oxygen carriers for the human body are growing. For instance, American Chemical Society researchers attempted to create synthetic red blood cells in June 2020 that replicate natural ones’ functions. These are the main trends that are now in the industry. One of the major factors impacting the growth of the industry is the lack of human blood for transfusions. A surgical procedure or traumatic injury results in the need for transfusions for more than 4.5 million Americans each year, and the demand for transfusions is outpacing the supply. The Pacific Heart, Lung, and Blood Institute reports that there is a severe shortage of human blood that can be used for medical procedures. In their lifetime, around 33.0% of Americans are predicted to require a transfusion due to a serious life-threatening condition. Since current projections do not account for the need for blood in situations of major civilian fatalities, terrorist attacks, and conflicts, which would drive market demand, the shortage in the coming years could be severe. Some Key Highlights from the Report : In September 2019, KaloCyte, a preclinical-stage biotech company working on creating a synthetic RBC replacement for use in situations where stored RBCs are not available, formed an association with Baltimore’s expanding biotech scene as a member of the University of Maryland (UM) BioPark. The hemoglobin obtained from a particular strain of E. coli bacterium is used to make synthetic hemoglobin-based replacements. In comparison to RBCs, the modified hemoglobin is more stable and has a better oxygen-carrying capacity. Low hemoglobin levels, percutaneous coronary intervention, coronary artery bypass grafting, non-ST-segment elevation acute coronary syndromes, and other conditions frequently require the administration of blood transfusions to patients. Thus, cardiovascular illnesses constitute a prominent application area for the market. The market for artificial blood substitutes is growing as a result of increasing strategic efforts by key market players to raise consumer awareness of these products. The artificial blood replacements market also offers you a thorough study of each country’s market growth. Additionally, it gives specific information about the positioning of market participants geographically. The historical timeframe for the data is from 2010 to 2019. Key participants include Hemarina, Sagart Corporation, FLUORO2 Therapeutics, Biopure Corporation, Alpha Therapeutic Corporation, KaloCyte, Baxter, Green Cross Corporation, North Field Laboratories, and Alliance Pharmaceutical Corporation, among others. Emergen Research has segmented the global synthetic blood substitutes market based on source, type, application, end-user, and region: Source Outlook (Revenue, USD Billion; 2017-2027) Human Blood Hemoglobin-Based Oxygen Carriers (HBOCs) Cardiovascular Diseases Hospitals & Clinics North America

Biopure Corporation Frequently Asked Questions (FAQ)

  • When was Biopure Corporation founded?

    Biopure Corporation was founded in 1984.

  • Where is Biopure Corporation's headquarters?

    Biopure Corporation's headquarters is located at 11 Hurley Street, Cambridge.

  • What is Biopure Corporation's latest funding round?

    Biopure Corporation's latest funding round is Dead.

  • How much did Biopure Corporation raise?

    Biopure Corporation raised a total of $107.13M.

  • Who are the investors of Biopure Corporation?

    Investors of Biopure Corporation include Nu Vision Holdings, Network Systems, Southridge Capital Management, Nite Capital Management, Downsview Capital and 14 more.

  • Who are Biopure Corporation's competitors?

    Competitors of Biopure Corporation include TIDI Products and 6 more.

Compare Biopure Corporation to Competitors

Yulex Logo

Yulex Corporation is a medical device company. It had developed the Yulex Latex Powder-free Exam Gloves.Yulex Corporation applies intelligent crop science and proprietary clean technology to create medical and biobased industrial products from guayule. Yulex natural rubber, produced from guayule, is replacing synthetic, petroleum-based materials as well as Hevea latex in a range of medical products.

TIDI Products Logo
TIDI Products

TIDI Products is a designer, developer, and manufacturer of medical devices focused on preventing infections and supporting caregivers across the acute care, alternate site and dental end-markets. The company was founded in 1969 and is based in Neenah, Wisconsin.

Artromick International

Artromick International is a provider of medication management services and technology. The company is a developer, manufacturer, and supplier of medication costs and related drug and medical supply distribution systems.

Lamda Biotech Logo
Lamda Biotech

Lamda Biotech develops and markets specialty research lab supplies and consults for special projects in molecular biology and functional genomics.

Action Medical

Action Medical Inc offers a range of first aid supplies such as medicine cabinets, first aid supplies, first aid kits, bandages, ointments, eye safety products, splints, infection control.

Homecare of Virginia

Homecare of Virginia is a medical supply company that aims to provide medical supplies to hospitals, government agencies and the military for more than 15 years.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.